Navigation Links
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Date:4/25/2008

RAZADYNE (galantamine) (trademark of Johnson & Johnson

("J&J"))

RAZADYNE ER (galantamine) (trademark of J&J)

REMINYL(R) (galantamine hydrobromide) (UK and Republic of

Ireland)

REMINYL (galantamine) (trademark of J&J, excluding UK

and Republic of Ireland)

REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of

Ireland)

REMINYL XL (galantamine) (trademark of J&J, excluding UK

and Republic of Ireland)

REPLAGAL(R) (agalsidase alfa)

SEASONIQUE (trademark of Barr Laboratories)

VYVANSE(TM) (lisdexamfetamine dimesylate)

XAGRID(R) (anagrelide hydrochloride)

The following are trademarks of third parties referred to in this press release:

Shire Product Active ingredient Trademark of

3TC (lamivudine) GSK

ZEFFIX (lamivudine) GSK

Overview of US GAAP Financial Results

1. Introduction

Summary of Q1 2008 Revenues from operations for the three months to March 31, 2008 increased by 33% to $702.2 million (2007: $528.2 million).

Operating income for the three months to March 31, 2008 was $163.0 million (2007: $141.2 million). The increase was primarily due to increased product sales in 2008 compared to 2007 partially offset by higher operating expenses as the Company increased its investment in its R&D projects and product launches.

Cash inflow from operating activities for the three months to March 31, 2008 decreased by 35% to $65.7 million (2007: $101.4 million). This decrease was primarily as a result of increased tax payments, and payments in respect of the 2003 TKT class action law suit during the three months to March 31, 2
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 The International Society for Medical ... society is continuing to accept abstracts for its ... Arlington, VA, April 19-21, 2010. This marks the ... to join the organization to submit an abstract ... is 12 AM EST, January 15, 2010. For ...
(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...
(Date:12/14/2009)... BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 ... ) and Amgen Inc.(Nasdaq: AMGN ) today ... Amgen exclusive worldwide rights to Array,s small-molecule glucokinase ... a Phase 1 clinical trial in patients with ... terms of the agreement, Array will receive an ...
(Date:12/14/2009)... State Biotech Leaders to Develop Blueprint to ... while Boosting Rhode Island,s Growing Biotech and ... Dec. 14 Several of Rhode ... and biotechnology gathered today at Brown University,s ... of medical innovation in Rhode Island and ...
Breaking Biology Technology:The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4
... cancer, patients quickly and effectively with ... Oct. 30 Beaumont Hospital, Royal Oak,(Royal Oak, ... the new,Elekta Axesse(TM), the ultimate whole-body cancer treatment ... therapeutic efficacy in,stereotactic radiation therapy, which involves three-dimensional ...
... 30 Sigma, a division of,Sigma-Aldrich(TM) (Nasdaq: ... Biology solutions through the new Ion Channel Solutions,Brochure ... addition to the most,comprehensive product line in this ... scientific information to assist in the elucidation of ...
... 30 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... underwritten offering of its,common stock to raise $60 million ... per share. All of the shares in the offering ... to close on November 2, 2007 and,the Company will ...
Other Biology Technology:Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 2Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 3Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 4Sigma Launches The New Ion Channel Solutions Brochure and Web Site 2Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering 2
(Date:12/15/2009)... at VIB and Ghent University in Flanders, Belgium have ... shock, the major cause of death in intensive care ... gas in mice with septic shock, researchers Anje Cauwels ... much less damage, while their chances of survival increased ... generally assumed that nitric oxide is responsible for the ...
(Date:12/15/2009)... release is available in German . , ... in predicting the future distribution of mammals. This is ... of 140 indigenous European mammals. The researchers analysed data ... well as the phylogenetic information of the species. Judging ... closely related species, mammals seem to adapt fast to ...
(Date:12/15/2009)... The PTR Group, a leading real-time and ... has agreed to sponsor three high school teams for ... ( http://usfirst.org ). ,, The PTR Group ... three different states. The teams from Atholton HS ... James Madison HS in Vienna, VA all have direct ...
Breaking Biology News(10 mins):Septic shock: Nitric oxide beneficial after all 2Species distribution models are of only limited value for predicting future mammal distributions 2The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2Nabors Industries Ltd Third Quarter 2009 Earnings Conference Call Invitation 56654 1Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference 13948 1Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference 13948 2Cements basic molecular structure finally decoded 9850 1Cements basic molecular structure finally decoded 9850 2Cements basic molecular structure finally decoded 9850 3
... PUBLICLY TRADED BROKERAGE TO UTILIZE TITANIUM,S ... SECURITY ... Bulletin Board: TTNUF), a leading biometric and security solutions,provider announced today ... (SHA: 600837). Titanium will install its,Biometrics Access Control System in Haitong,s ...
... By peering deep into evolutionary history, scientists at the ... of photosensitivity in animals. , The findings are ... PLoS ONE. The scientists studied the aquatic animal Hydra, ... existed for hundreds of millions of years. The authors ...
... have shown how tiny "nanorods" of gold can be triggered ... of tumor cells, setting in motion a complex biochemical mechanism ... membranes often have an abnormally high number of receptor sites ... of vitamin B that many tumor cells crave. The Purdue ...
Other Biology News:Titanium Group Announces Contract With Haitong Securities 2Titanium Group Announces Contract With Haitong Securities 3Titanium Group Announces Contract With Haitong Securities 4UCSB researchers discover the dawn of animal vision 2Gold nanorods shed light on new approach to fighting cancer 2Gold nanorods shed light on new approach to fighting cancer 3
... Mouse Cytokine Array is a multiplex sandwich ... measurement of 12 cytokines in serum; EDTA, ... Each well of the microplate provided is ... in standards and samples added to the ...
... is designed for the fast and simple ... at any position (for the generation of ... is designed to allow neomycin / kanamycin ... combines a prokaryotic promoter (gb2) for expression ...
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: